Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-05231023 (Pfizer)
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
PF-05231023 (also known as CVX-343) is a long-acting, antibody-conjugated fibroblast growth factor 21 (FGF21) mimetic developed by Pfizer and CovX. It consists of two engineered human FGF21 molecules covalently linked to the Fab region of a humanized IgG1 scaffold antibody (CVX-2000). PF-05231023 acts as an agonist of the FGF21 receptor complex, which comprises the co-receptor beta-klotho (KLB) and fibroblast growth factor receptors (primarily FGFR1c, but also FGFR2c and FGFR3c). It was developed for the treatment of type 2 diabetes mellitus, obesity, and hyperlipidemia. Although it demonstrated favorable lipid-lowering effects and modest weight loss in clinical trials, its development was discontinued due to safety concerns, including increases in blood pressure and heart rate, as well as shifts in bone turnover biomarkers.
- Other names
- FGF21-CovX body conjugateFGF-21-CovX body conjugateFGF 21-CovX body conjugateFGF21 protein-CVX-2000 monoclonal antibody conjugateFGF-21 protein-CVX-2000 monoclonal antibody conjugateFGF 21 protein-CVX-2000 monoclonal antibody conjugate
02
Targets
KLB (Beta-Klotho)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on PF-05231023 (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-05231023 (Pfizer).